EE91 Economic Evaluation of Durvalumab for the Treatment of Patients With Stage III Unresectable Locally Advanced Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Platinum-Based Chemoradiation Therapy
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.343
https://www.valueinhealthjournal.com/article/S1098-3015(22)02547-5/fulltext
Title :
EE91 Economic Evaluation of Durvalumab for the Treatment of Patients With Stage III Unresectable Locally Advanced Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Platinum-Based Chemoradiation Therapy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02547-5&doi=10.1016/j.jval.2022.09.343
First page :
Section Title :
Open access? :
No
Section Order :
12157